1. Home
  2. SNY vs VEEV Comparison

SNY vs VEEV Comparison

Compare SNY & VEEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNY
  • VEEV
  • Stock Information
  • Founded
  • SNY 1994
  • VEEV 2007
  • Country
  • SNY France
  • VEEV United States
  • Employees
  • SNY N/A
  • VEEV N/A
  • Industry
  • SNY Biotechnology: Pharmaceutical Preparations
  • VEEV Computer Software: Prepackaged Software
  • Sector
  • SNY Health Care
  • VEEV Technology
  • Exchange
  • SNY Nasdaq
  • VEEV Nasdaq
  • Market Cap
  • SNY 113.4B
  • VEEV 48.0B
  • IPO Year
  • SNY N/A
  • VEEV 2013
  • Fundamental
  • Price
  • SNY $46.97
  • VEEV $274.44
  • Analyst Decision
  • SNY Buy
  • VEEV Buy
  • Analyst Count
  • SNY 4
  • VEEV 29
  • Target Price
  • SNY $61.50
  • VEEV $295.07
  • AVG Volume (30 Days)
  • SNY 2.7M
  • VEEV 1.5M
  • Earning Date
  • SNY 10-24-2025
  • VEEV 08-27-2025
  • Dividend Yield
  • SNY 3.40%
  • VEEV N/A
  • EPS Growth
  • SNY 118.56
  • VEEV 29.60
  • EPS
  • SNY 8.65
  • VEEV 4.86
  • Revenue
  • SNY $53,714,621,258.00
  • VEEV $2,968,217,000.00
  • Revenue This Year
  • SNY $1.53
  • VEEV $16.58
  • Revenue Next Year
  • SNY $7.06
  • VEEV $11.77
  • P/E Ratio
  • SNY $5.43
  • VEEV $56.35
  • Revenue Growth
  • SNY 15.65
  • VEEV 15.33
  • 52 Week Low
  • SNY $44.73
  • VEEV $200.30
  • 52 Week High
  • SNY $60.12
  • VEEV $296.72
  • Technical
  • Relative Strength Index (RSI)
  • SNY 43.02
  • VEEV 46.04
  • Support Level
  • SNY $46.50
  • VEEV $273.49
  • Resistance Level
  • SNY $47.69
  • VEEV $283.29
  • Average True Range (ATR)
  • SNY 0.68
  • VEEV 6.82
  • MACD
  • SNY -0.18
  • VEEV -0.18
  • Stochastic Oscillator
  • SNY 36.14
  • VEEV 48.59

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

About VEEV Veeva Systems Inc.

Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.

Share on Social Networks: